Dr. Eric Leire

Dr. Eric Leire brings to the board of directors of Inhatarget a solid biotechnology expertise through a diverse experience: with pharmaceutical oncology companies (Pfizer, Schering Plough, Pharmacia), with biotechnology companies (CEO of several private and public US-based biotech companies such as APT Therapeutics, Paringenix), with academia (Research Associate at the Harvard AIDS Institute) and with the Private Equity industry (partner at Biofund Venture Capital).  He is the inventor of several medical patents and author of several scientific publications. He also serves on the board of other European biotechnology companies (Immunethep, BSIM, Pherecydes listed on Euronext). Furthermore, Dr Eric Leire has been CEO of several gene and cell therapy companies developing cancer therapies such as Enochian Biosciences (Nasdaq: ENOB) and DanDrit Biotechnologies (OTC.QB:DDRT). He is the founder and CEO of Genflow Biosciences, a biotechnology company listed on the London Stock Exchange (GENF.L).  He holds an MD from Grenoble University and an MBA from HEC, Paris and Kellogg, Northwestern University in Chicago, USA.